Phuturdex › Drugs › Brepocitinib
Drugs in development · updated 12 November 2026
Brepocitinib: clinical trials and development status
Other names and codes: Lisraya
As of 12 November 2026 Brepocitinib is in 3 active clinical trials (recruiting or ongoing, phases I–III) for 5 diseases. The most advanced phase is III.
Authorisation
- EU not available
- Italy not available
- Germany not available
- US yes (FDA)
Sources: EMA, AIFA register (open data), FDA. For Germany only the EU centralised authorisation is shown: the national BfArM register is not one of our sources.
Map of sites in Europe with recruitment status, every trial and an email when something changes. Full access free until 31 March 2027, no card needed.
Approved uses in the United States (FDA)
LISRAYA is indicated for the treatment of dermatomyositis in adult patients. LISRAYA is a Janus kinase (JAK) and tyrosine kinase 2 (TYK2) inhibitor indicated for the treatment of dermatomyositis in adult patients. Limitations of Use LISRAYA is not recommended for use in combination with other JAK inhibitors, other TYK2 inhibitors, or biologic DMARDs. Limitations of Use LISRAYA is not recommended for use in combination with other JAK inhibitors, other TYK2 inhibitors, or biologic DMARDs.
Source: FDA label of Lisraya, section «Indications and Usage» (openFDA), version of 5 November 2026
Official documents
- Lisraya: FDA label (DailyMed) · FDA version of 5 November 2026
Use, doses, side effects and interactions: only these official documents are authoritative.
Diseases studied
For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.
| Disease | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Intermediate uveitis | III | 1 | NCT06431373 |
| Lichen planus | II–III | 1 | NCT07532603 |
| Posterior uveitis | III | 1 | NCT06431373 |
| Sarcoidosis | II–III | 1 | NCT06978725 |
| Uveitis | III | 1 | NCT06431373 |
Sites in Europe
36 sites of the active trials in 9 European countries, 7 recruiting.
- United Kingdom15
- Germany6
- Hungary4
- Italy4
- Spain3
- Austria1
- Belgium1
- Czechia1
- and 1 more
Sites declared by the sponsors on ClinicalTrials.gov; region worked out by Phuturdex from the geographic point. The list of sites with city and recruitment status is in the app. See the sites →
Everything on Brepocitinib
In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.
Open in Phuturdex →Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 12 November 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, refers to the United States and is a Phuturdex calculation described on the Method page, not official data: the drug may already be marketed in other countries.